Iovance Biotherapeutics, Inc., a biotechnology company operating within the Health Care sector, specializes in the development and commercialization of innovative cancer immunotherapies. These therapies specifically target tumor-infiltrating lymphocytes to treat cancer patients. The company is publicly traded on the Nasdaq under the ticker symbol IOV, with its financials denominated in USD.
As of December 25, 2025, Iovance Biotherapeutics closed its most recent trade at $2.85. This price represents a significant decline of approximately 35% from its 52-week high of $8.15, recorded on January 1, 2025. Conversely, the closing price is 73% above the 52-week low of $1.64, observed on May 18, 2025. The company’s market capitalization stands at $1.13 billion, reflecting its current valuation in the market.
The financial metrics of Iovance Biotherapeutics indicate modest growth expectations. The price-to-earnings (P/E) ratio is reported at -2.37, highlighting the company’s negative earnings. This negative P/E ratio suggests that the company is not currently generating profits, which is a critical consideration for investors. Additionally, the price-to-book (P/B) ratio is 1.58, indicating that the market values the company at slightly more than its book value.
In a recent corporate disclosure dated December 19, 2025, Iovance Biotherapeutics announced the receipt of inducement grants in accordance with NASDAQ Rule 5635(c)(4). This rule pertains to the maintenance of a minimum bid price for listed securities, and the receipt of such grants is a measure to ensure compliance. No further updates on earnings or guidance have been provided since this announcement.
The price movement of Iovance Biotherapeutics over the past year has exhibited considerable volatility. The current trading price, situated mid-range within the yearly spectrum, suggests a moderate valuation relative to the historical highs and lows. The negative earnings metric underscores the importance of evaluating the company’s cash-flow prospects carefully, as it reflects the challenges in achieving profitability.
Overall, Iovance Biotherapeutics remains focused on its core mission of advancing cancer immunotherapies, despite the financial challenges indicated by its current earnings and market valuation. Investors and stakeholders are advised to monitor the company’s progress in clinical developments and market strategies closely, as these factors will be pivotal in shaping its future financial performance.
